
Formats: [HTML](/news/2015/05/6/alexion-pharmaceuticals-agrees-to-purchase-synageva-biopharma-a-maker-of-rare-disease-treatments-for-us-8-6-billion.html)  [JSON](/news/2015/05/6/alexion-pharmaceuticals-agrees-to-purchase-synageva-biopharma-a-maker-of-rare-disease-treatments-for-us-8-6-billion.json)  [XML](/news/2015/05/6/alexion-pharmaceuticals-agrees-to-purchase-synageva-biopharma-a-maker-of-rare-disease-treatments-for-us-8-6-billion.xml)  

### [2015-05-6](/news/2015/05/6/index.md)

##### Alexion Pharmaceuticals
# Alexion Pharmaceuticals agrees to purchase Synageva BioPharma, a maker of rare disease treatments, for US$8.6 billion. 

The drug makerâ€™s offer for Synageva has a huge 136 percent premium. Still, exchanging a chunk of high-priced paper for assets may be a savvy move.


### Sources:

1. [New York Times](https://www.nytimes.com/2015/05/07/business/dealbook/alexion-puts-its-soaring-stock-price-to-good-use.html)
1. [Cover Image](https://static01.nyt.com/images/icons/t_logo_291_black.png)
